Innovation | Novartis United States of America

Media Release
Mar 22, 2014

Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients
Media Release
Mar 21, 2014

Novartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
Media Release
Mar 21, 2014

Novartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
Media Release
Jan 09, 2014

Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
Media Release
Jan 09, 2014

Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
Media Release
Dec 07, 2013

Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
Media Release
Dec 07, 2013

Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
Media Release
Oct 28, 2013

Novartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure Caregivers
Media Release
Oct 28, 2013

Novartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure Caregivers
Media Release
Sep 23, 2013

Novartis announces new data on the effects of investigational RLX030 on kidney blood flow in chronic heart failure patients
Media Release
Sep 23, 2013

Novartis announces new data on the effects of investigational RLX030 on kidney blood flow in chronic heart failure patients
Media Release
Jun 28, 2013

Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer's disease

‹ Previous page
1
…
37
38
39
40
41
42
43
…
53
› Next page